A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Summary

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Timeline

Start

2023-03-10

Primary completion

2024-10-07

Completion

2025-08-13

Outcome

Met primary endpoint

registry analysis (superiority test); Vehicle Cream BID to Ruxolitinib 1.5% Cream BID vs Ruxolitinib 1.5% Cream BID to Ruxolitinib 1.5% Cream BID; p = 0.0003 NCT05755438 ↗

release “The TRuE-PN1 study met its primary endpoint” incyte.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	Topical

Indications